ALLMedicine™ Alopecia Universalis Center
Research & Reviews 119 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979079
JAMA Dermatology; Sy N, Mastacouris N et. al.
Mar 2nd, 2023 - Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) are poorly established. To estimate overall and subgroup prevalences of AA and its subtypes. This cross-sectional study using electronic records comprising t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979012
JAMA Dermatology; Mostaghimi A, Gao W et. al.
Mar 2nd, 2023 - Alopecia areata (AA) is characterized by nonscarring hair loss of the scalp, face, and/or body. Alopecia totalis (AT) and alopecia universalis (AU) involve complete loss of the scalp and body hair, respectively. The epidemiology of AA in the US re...
https://clinicaltrials.gov/ct2/show/NCT04011748
Jan 12th, 2023 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.8 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...
https://www.mdedge.com/dermatology/article/260391/hair-nails/study-evaluates-features-alopecia-areata-hispanic/latinx
Doug Brunk
Dec 29th, 2022 - Among Hispanic/Latinx patients with alopecia areata, the mean age at diagnosis was 33 years, 24% had concomitant atopy, and 18% had one or more coexisting autoimmune conditions, most commonly rheumatoid arthritis. Those are among key findings from.
https://www.mdedge.com/dermatology/article/259630/hair-nails/dupilumab-therapeutic-approach-alopecia-universalis
Michael J. Visconti, DO, Adam Richardson, DO et. al.
Nov 21st, 2022 - To the Editor: Atopic diseases, specifically atopic dermatitis (AD) and alopecia areata (AA), are at the forefront of a new era in dermatology involving molecular-directed therapy. Dupilumab is one specific example, having received US Food and Dru.
Clinicaltrials.gov 14 results
https://clinicaltrials.gov/ct2/show/NCT04011748
Jan 12th, 2023 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.8 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...
https://clinicaltrials.gov/ct2/show/NCT05587257
Oct 20th, 2022 - Alopecia areata (AA) is the most common cause of non-scarring alopecia. (Hordinsky, 2013). Although many patients improve spontaneously or respond to standard therapy, in patients with more severe and refractory disease, management can be quite ch...
https://clinicaltrials.gov/ct2/show/NCT05496426
Aug 11th, 2022 - This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).
https://clinicaltrials.gov/ct2/show/NCT04238091
Mar 21st, 2022 - Alopecia areata (AA) is an autoimmune condition resulting in chronic and relapsing hair loss. AA patchy is associated with well-circumscribed patches of hair loss, commonly on the scalp or face, while alopecia totalis (AT) and alopecia universalis...
https://clinicaltrials.gov/ct2/show/NCT04833179
Apr 6th, 2021 - Alopecia areata (AA) is a common autoimmune disease that triggers non scarring hair loss in different severities. Usually the hair loss will be contained to the scalp and / or beard, but in some cases, there will be total hair loss from the entire...
News 32 results
https://www.mdedge.com/dermatology/article/260391/hair-nails/study-evaluates-features-alopecia-areata-hispanic/latinx
Doug Brunk
Dec 29th, 2022 - Among Hispanic/Latinx patients with alopecia areata, the mean age at diagnosis was 33 years, 24% had concomitant atopy, and 18% had one or more coexisting autoimmune conditions, most commonly rheumatoid arthritis. Those are among key findings from.
https://www.mdedge.com/dermatology/article/259630/hair-nails/dupilumab-therapeutic-approach-alopecia-universalis
Michael J. Visconti, DO, Adam Richardson, DO et. al.
Nov 21st, 2022 - To the Editor: Atopic diseases, specifically atopic dermatitis (AD) and alopecia areata (AA), are at the forefront of a new era in dermatology involving molecular-directed therapy. Dupilumab is one specific example, having received US Food and Dru.
https://www.mdedge.com/dermatology/article/256923/hair-nails/unique-treatment-alopecia-areata-combining-epinephrine
Eugeniu Stratulat, MD, Terri Shih, BS et. al.
Aug 9th, 2022 - Alopecia areata (AA) is an autoimmune disorder characterized by transient hair loss with preservation of the hair follicle (HF). The lifetime incidence risk of AA is approximately 2%,1 with a mean age of onset of 25 to 36 years and with no clinica.
https://www.mdedge.com/familymedicine/article/254363/dermatology/focal-hair-loss
MDedge Family Medicine;
May 5th, 2022 - The findings of smooth, round alopecia occurring rapidly without associated scarring, pain, or itching, is consistent with the diagnosis of alopecia areata. Alopecia areata is a common autoimmune disease caused by T lymphocytes targeting hair foll.
https://www.medscape.com/viewarticle/960162
Oct 4th, 2021 - Baricitinib, an oral inhibitor of Janus kinase (JAK) types 1 and 2, produced substantial rates of hair growth with acceptable tolerability for patients with alopecia areata, according to the results of two phase 3 trials presented at the European ...